10x Genomics, Inc. (TXG) Stock Price & Analysis
10x Genomics, Inc. (TXG) rose 4.83% to USD 30.59 as of June 10, 2026 at 02:25 UTC, according to Nexqual real-time market data.
TXG last closed at USD 29.18; the session ranged USD 28.65–30.87 on volume of 3,185,007 shares. Market capitalization is $3.88B, with a 52-week range of USD 10.17–35.65 (NMS). Source: Nexqual, June 10, 2026 at 02:25 UTC.
Key Statistics (as of June 10, 2026 at 02:25 UTC)
| Price | USD 30.59 |
|---|---|
| Change | ▲ 4.83% (up) |
| Previous Close | USD 29.18 |
| Open | USD 29.42 |
| Day Range | USD 28.65 – 30.87 |
| 52-Week Range | USD 10.17 – 35.65 |
| Volume | 3,185,007 shares |
| Market Cap | $3.88B |
| Exchange | NMS |
Technical Analysis (TXG)
Nexqual's technical model rates TXG "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:25 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.1 (neutral) |
| vs SMA50 | Above (USD 24.01) |
| MACD | 2.39 (positive) |
Analyst Ratings (TXG)
Wall Street analysts rate TXG "Buy" based on 13 analysts, with a mean price target of USD 25.77 (range USD 20–32), per Nexqual as of June 10, 2026 at 02:25 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 25.77 |
| High Target | USD 32 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 6 / 10 / 0 |
Earnings (TXG)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.02 |
| Revenue Estimate | $146.61M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.07 vs est -0.06 ▲ beat |
| 2025-12-31 | USD 0.07 vs est -0.04 ▲ beat |
| 2025-09-30 | USD -0.02 vs est -0.07 ▲ beat |
| 2025-06-30 | USD 0.48 vs est -0.08 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Financials & Fundamentals (TXG)
| Total Revenue | $638.78M |
|---|---|
| Revenue Growth (YoY) | -2.60% |
| Gross Margin | +69.68% |
| Operating Margin | -11.30% |
| Profit Margin | -3.55% |
| ROE | -2.98% |
| Debt / Equity | 10 |
| Current Ratio | 5.9 |
| Total Cash | $539.85M |
| Total Debt | $81.39M |
| Free Cash Flow | $124.55M |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Financial Health Score (TXG)
Nexqual rates 10x Genomics, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 02:25 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 70%, operating -11% |
| Balance Sheet | Strong — $540M cash vs $81M debt, net cash position |
| Cash Flow | Strong — FCF $125M, 19% margin |
| Efficiency | Critical — ROE -3%, ROA -4.5% |
Ownership (TXG)
| Insider Ownership | +1.63% |
|---|---|
| Institutional Ownership | +113.75% |
| Shares Outstanding | 116.88M |
| Float | 115.09M |
| Short % of Float | +19.29% |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Leadership (TXG)
10x Genomics, Inc. is led by Serge Saxonov (age 48), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 02:25 UTC.
| Co-Founder, CEO & Director | Serge Saxonov (age 48) |
|---|---|
| Co-Founder, President, Chief Scientific Officer & Director | Benjamin J. Hindson (age 50) |
| CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | Adam S. Taich (age 50) |
| Founding Scientist & CTO | Michael Schnall-Levin |
| Associate Director of Product Management | Jens Durruthy |
Major Backers & Investors (TXG)
Notable institutional backers of 10x Genomics, Inc. include ARK Invest, FMR, LLC, Quantinno Capital Management, LP, according to Nexqual as of June 10, 2026 at 02:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 18.51% |
| FMR, LLC | 15.18% |
| Quantinno Capital Management, LP | 4.63% |
| Fidelity | 4.49% |
| Sumitomo Mitsui Trust Group, Inc. | 4.37% |
| Amova Asset Management Americas Inc | 4.37% |
| Goldman Sachs | 3.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.24% |
| BlackRock | 10.89% |
| Geode Capital | 2.48% |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
From 10x Genomics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)
Key Strengths & Strategy (as disclosed to the SEC)
- 10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
- The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.
- It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample.
- This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
| BEAM | Beam Therapeutics Inc. | USD 30.47 | ▲ 3.64% |
| PACB | Pacific Biosciences of Californ | USD 1.37 | ▼ 5.52% |
| VCYT | Veracyte, Inc. | USD 49.24 | ▲ 1.05% |
| GH | Guardant Health, Inc. | USD 130.12 | ▲ 3.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:25 UTC. This page is informational and not investment advice.